Literature DB >> 21846619

American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Acromegaly--2011 update: executive summary.

Laurence Katznelson1, John L D Atkinson, David M Cook, Shereen Z Ezzat, Amir H Hamrahian, Karen K Miller.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21846619     DOI： 10.4158/ep.17.4.636

Source DB:  PubMed          Journal:  Endocr Pract        ISSN： 1530-891X            Impact factor:   3.443


× No keyword cloud information.
  33 in total

1.  Pre-surgical treatment with somatostatin analogues in patients with acromegaly: the case against.

Authors:  M Losa; V G Crippa
Journal:  J Endocrinol Invest       Date:  2012-06       Impact factor: 4.256

Review 2.  Expert consensus document: A consensus on the medical treatment of acromegaly.

Authors:  Andrea Giustina; Philippe Chanson; David Kleinberg; Marcello D Bronstein; David R Clemmons; Anne Klibanski; Aart J van der Lely; Christian J Strasburger; Steven W Lamberts; Ken K Y Ho; Felipe F Casanueva; Shlomo Melmed
Journal:  Nat Rev Endocrinol       Date:  2014-02-25       Impact factor: 43.330

3.  Evidence of dysexecutive syndrome in patients with acromegaly.

Authors:  Shaobo Shan; Lingling Fang; Jia Huang; Raymond C K Chan; Guijun Jia; Weiqing Wan
Journal:  Pituitary       Date:  2017-12       Impact factor: 4.107

Review 4.  The surgical treatment of acromegaly.

Authors:  Michael Buchfelder; Sven-Martin Schlaffer
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

5.  Daily life reflections of acromegaly guidelines.

Authors:  T Apaydin; H M Ozkaya; F E Keskin; O A Haliloglu; K Karababa; S Erdem; P Kadioglu
Journal:  J Endocrinol Invest       Date:  2016-10-20       Impact factor: 4.256

6.  The effects of high serum growth hormone and IGF-1 levels on bone mineral density in acromegaly.

Authors:  S Tuzcu; Ş A Durmaz; A Carlıoğlu; Z Demircan; A Tuzcu; C Beyaz; A Tay
Journal:  Z Rheumatol       Date:  2017-10       Impact factor: 1.372

7.  Acromegaly is associated with high fibroblast growth factor-21 levels.

Authors:  B S Yurekli; N O Kutbay; M Aksit; A Suner; I Y Simsir; S Seckiner; G U Kocabas; G Bozkaya; F Saygili
Journal:  J Endocrinol Invest       Date:  2018-05-12       Impact factor: 4.256

Review 8.  Management options for persistent postoperative acromegaly.

Authors:  Nestoras Mathioudakis; Roberto Salvatori
Journal:  Neurosurg Clin N Am       Date:  2012-08-09       Impact factor: 2.509

Review 9.  Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene.

Authors:  Albert Beckers; Lauri A Aaltonen; Adrian F Daly; Auli Karhu
Journal:  Endocr Rev       Date:  2013-01-31       Impact factor: 19.871

10.  Monomorphous Plurihormonal Pituitary Adenoma of Pit-1 Lineage in a Giant Adolescent with Central Hyperthyroidism.

Authors:  Bernardo Dias Pereira; Luísa Raimundo; Ozgur Mete; Ana Oliveira; Jorge Portugal; Sylvia L Asa
Journal:  Endocr Pathol       Date:  2016-03       Impact factor: 3.943
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.